Abbott receives EUA for its rapid COVID-19 antigen self-test BinaxNOW
Category: #health  By Nikita Chaurasia  Date: 2021-04-05
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Abbott receives EUA for its rapid COVID-19 antigen self-test BinaxNOW
  • Individuals with or without COVID-19 signs can get BinaxNOW without the need for a prescription.
  • Abbott is reportedly planning to deliver BinaxNOW to major consumer goods retailers.

American multinational medical device company Abbott Laboratories has announced to have received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for BinaxNOW, a self-test antigen for detecting COVID-19.

Individuals with or without COVID-19 signs can get this test without the need for a prescription. In the coming weeks, Abbott is reportedly planning to deliver BinaxNOW to major food, pharmacy, and mass merchandiser retailers. The test will also be available on some of the retailers’ websites.

For those unaware, the BinaxNOW Self-Test, which provides results in just 15 minutes, allows people who have tested positive to isolate themselves immediately, rather than waiting days for lab results or sending away at-home tests.

The test can be used on children as well as all among adults aged 15 and above. Moreover, BinaxNOW will be packaged in a two-count box in order to fulfill serial testing criteria.

Robert B. Ford, President, and CEO at Abbott reportedly stated that when paired with vaccination, the BinaxNOW Self-Test will aid Americans to resume their daily chores.

Initially, Abbott had rolled out the BinaxNOW technical test across the United States and expanded its production across all its manufacturing facilities to 50 million tests every month.

The U.S. Department of Health and Human Services (HHS) had bought the company's first 150 million tests and distributed them to nursing homes, K-12 schools, as well as underserved populations, where they are still in use today and are considered to be a valuable tool in the battle against the Coronavirus.

In similar developments, American manufacturer of diagnostic healthcare products Quidel Corporation has also announced that the FDA has granted its QuickVue® At-Home OTC COVID-19 test an Emergency Use Authorization.

Source Credit –

https://www.benzinga.com/pressreleases/21/03/n20438966/abbotts-binaxnow-rapid-antigen-self-test-receives-fda-emergency-use-authorization-for-asymptomatic

 

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

By Nikita Chaurasia

The McPlant patty is developed in collaboration with Beyond Meat Inc. It will be prepared using vegetarian ingredients like peas, potatoes, and rice. McDonald’s will reportedly start offering its first vegetarian option in the U.S., the ne...